<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="406">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604249</url>
  </required_header>
  <id_info>
    <org_study_id>RINCOVID</org_study_id>
    <nct_id>NCT04604249</nct_id>
  </id_info>
  <brief_title>Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World</brief_title>
  <acronym>RINCOVID</acronym>
  <official_title>Prevalence of COVID-19 and Risk Factors Associated With Seroconversion in La Rinconada, the Highest City of the World - 5,100 m</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Expertise sur l'Altitude EXALT</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d'Expertise sur l'Altitude EXALT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the beginning of 2020, SARS-CoV-2 outbreak spread over the world, conducting in a&#xD;
      pandemic state declared by the world health organization in March 2020. Conflicting data have&#xD;
      been yet published regarding to the incidence rate of COVID-19 infection in altitude. Mainly&#xD;
      based on analysis from national Peru database, some authors argued that COVID-19 disease, as&#xD;
      well as case fatality rate was less frequent in altitude. However, epidemiological data are&#xD;
      lacking regarding to the prevalence of COVID-19 in altitude, and more specially in high&#xD;
      altitude.&#xD;
&#xD;
      Aim of this cross-sectional study is to assess the prevalence of seroconversion for the&#xD;
      SARS-CoV-2 in the population of La Rinconada, a mining town at 5,100 m, the highest city in&#xD;
      the world.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. Prevalence of seroconversion for SARS-CoV-2.</measure>
    <time_frame>Through study completion, an average of 1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Occupational and environmental exposures associated with SARS-CoV-2 seroconversion.</measure>
    <time_frame>Through study completion, an average of 1 week</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <condition>High Altitude</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)</intervention_name>
    <description>Presence of specific SARS-CoV-2 antibodies (IgM or IgG).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inhabitants of La Rinconda, coming to a medical consultation connected to a scientific&#xD;
        research project (Expedition5300).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Age &gt; 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years.&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>La Rinconada</name>
      <address>
        <city>Puno</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <results_reference>
    <citation>Castagnetto JM, Segovia-Juarez J, Gonzales GF. Letter to the Editor: COVID-19 Infections Do Not Change with Increasing Altitudes from 1,000 to 4,700 m. High Alt Med Biol. 2020 Dec;21(4):428-430. doi: 10.1089/ham.2020.0173. Epub 2020 Oct 13.</citation>
    <PMID>33054403</PMID>
  </results_reference>
  <results_reference>
    <citation>Seclén SN, Nunez-Robles E, Yovera-Aldana M, Arias-Chumpitaz A. Incidence of COVID-19 infection and prevalence of diabetes, obesity and hypertension according to altitude in Peruvian population. Diabetes Res Clin Pract. 2020 Nov;169:108463. doi: 10.1016/j.diabres.2020.108463. Epub 2020 Sep 22.</citation>
    <PMID>32971150</PMID>
  </results_reference>
  <results_reference>
    <citation>Segovia-Juarez J, Castagnetto JM, Gonzales GF. High altitude reduces infection rate of COVID-19 but not case-fatality rate. Respir Physiol Neurobiol. 2020 Oct;281:103494. doi: 10.1016/j.resp.2020.103494. Epub 2020 Jul 15.</citation>
    <PMID>32679369</PMID>
  </results_reference>
  <results_reference>
    <citation>Woolcott OO, Bergman RN. Mortality Attributed to COVID-19 in High-Altitude Populations. High Alt Med Biol. 2020 Dec;21(4):409-416. doi: 10.1089/ham.2020.0098. Epub 2020 Aug 17.</citation>
    <PMID>32815745</PMID>
  </results_reference>
  <results_reference>
    <citation>Intimayta-Escalante C, Rojas-Bolivar D, Hancco I. Letter to the Editor: Influence of Altitude on the Prevalence and Case Fatality Rate of COVID-19 in Peru. High Alt Med Biol. 2020 Dec;21(4):426-427. doi: 10.1089/ham.2020.0133. Epub 2020 Aug 14.</citation>
    <PMID>32803989</PMID>
  </results_reference>
  <results_reference>
    <citation>Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raduan F, Carvajal-Rodriguez F, Dutschmann M, Schneider-Gasser EM, Zubieta-Calleja G, Soliz J. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? Respir Physiol Neurobiol. 2020 Jun;277:103443. doi: 10.1016/j.resp.2020.103443. Epub 2020 Apr 22.</citation>
    <PMID>32333993</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevalence</keyword>
  <keyword>Covid-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Hight altitude</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

